Selank

Amino Acid Sequence:

Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro

Chemical Formula:

C₃₃H₅₇N₁₁O₉

CAS Registry Number:

129954‑34‑3

• Anxiolytic effects via GABA modulation

• Cognitive enhancement & memory support

• Stress‑response regulation

• Neuroimmune modulation

• Antidepressant‑adjunct potential

• Monoamine stabilization

• Neuroprotection in stress‑related dysfunction

Neurotransmitter Modulation

• Enhances GABAergic signaling (primary anxiolytic pathway)

• Stabilizes serotonin and dopamine metabolism

• Supports balanced monoamine turnover under stress

Nootropic & Cognitive Effects

• Increases neurotrophic factor expression

• Supports memory formation and cognitive performance

• Enhances stress resilience and mental clarity

Neuroimmune Modulation

• Balances pro‑ and anti‑inflammatory cytokines

• Supports immune‑nervous system communication

• Helps maintain homeostasis during chronic stress

Selank is not FDA‑approved and is considered an experimental neuropeptide in Western research. However, it has been widely studied and utilized in Eastern European clinical settings, where it has developed a strong reputation for safety and tolerability. Its combination of favorable early findings and substantial anecdotal interest continues to drive scientific exploration into its anxiolytic, cognitive, and neuroimmune applications.

1. Ashmarin, I. P., Kamensky, A. A., & Yakhno, N. N. (1995). Tuftsin and tuftsin‑related peptides in neuroimmune regulation. Neuroscience and Behavioral Physiology, 25(4), 341–345.

2. Kozlovskii, V. I., Neznamov, G. G., & Kamensky, A. A. (2002). Clinical evaluation of Selank in generalized anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 102(5), 30–35.

3. Andreeva, L. A., et al. (2010). Selank’s effects on serotonin and dopamine metabolism in stress models. Bulletin of Experimental Biology and Medicine, 149(5), 612–615.

4. Dolotov, O. V., et al. (2011). Mechanisms of Selank’s anxiolytic action: modulation of GABAergic activity. Neuroscience and Behavioral Physiology, 41(6), 639–643.

5. Inozemtseva, L. S., et al. (2013). Selank’s influence on cytokine expression and immune balance. Bulletin of Experimental Biology and Medicine, 155(2), 241–244.

6. Kamensky, A. A., et al. (2016). Neuroprotective properties of Selank in chronic stress models. Neuroscience and Behavioral Physiology, 46(8), 1001–1007.

7. Neznamov, G. G., & Teleshova, E. S. (2009). Comparative clinical study of Selank and benzodiazepines in anxiety disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 109(3), 22–27.

CURRENT BATCH LOT NUMBER: SK102026-05-04

CERTIFICATE OF ANALYSIS – TGMPURE Selank 10 MG (SK102026-05-04)